Nuprin wasn’t pulled from the market for safety reasons. It was quietly discontinued in the early 2000s because it couldn’t compete with Advil and Motrin IB, the two dominant over-the-counter ibuprofen brands that steadily overtook it in sales. The product itself, standard 200 mg ibuprofen tablets, was never the problem. The brand simply lost the marketing and shelf-space battle.
What Nuprin Actually Was
Nuprin was one of the first over-the-counter ibuprofen products available in the United States. When the FDA approved ibuprofen for nonprescription sale in 1984, Nuprin launched alongside Advil as a way for consumers to buy the same anti-inflammatory painkiller that had previously required a prescription. It was manufactured by Bristol-Myers (later Bristol-Myers Squibb) and contained the same 200 mg dose of ibuprofen found in every competing brand.
The brand became well known through its memorable “Little. Yellow. Different.” advertising campaign in the late 1980s. The commercials emphasized the tablet’s distinctive small yellow coating to set it apart visually from competitors. For a time, the campaign gave Nuprin strong name recognition and a real presence in drugstore aisles.
How Advil and Motrin IB Won the Market
The OTC ibuprofen market quickly became a three-way race between Nuprin, Advil, and Motrin IB. All three products contained the exact same active ingredient at the same dose. The competition came down entirely to branding, advertising budgets, and retail distribution.
Advil, backed by American Home Products (later Wyeth), invested heavily in marketing and built the strongest consumer loyalty. Motrin IB had the advantage of name recognition from the prescription version of Motrin, which doctors had been writing for years. Bristol-Myers Squibb, meanwhile, had a massive portfolio of consumer health products and pharmaceutical drugs, and Nuprin wasn’t a top priority for marketing investment. By the mid-1990s, Nuprin’s market share had fallen significantly, and the gap kept widening.
Store-brand and generic ibuprofen also ate into the market. Once consumers understood that all OTC ibuprofen was the same drug, many switched to cheaper alternatives. This price pressure hurt all branded products, but it hit the weakest brand hardest. Bristol-Myers Squibb eventually stopped producing Nuprin without a major public announcement, letting the brand fade from shelves rather than making a dramatic exit.
No Safety Recall Was Involved
Because the name simply disappeared, some people assume Nuprin was recalled or found to be unsafe. That’s not the case. Ibuprofen carries the same risks it always has, including potential stomach irritation, kidney effects with long-term use, and cardiovascular concerns at high doses. But none of these issues were specific to Nuprin. The yellow coating that made the tablets distinctive was a cosmetic difference, not a formulation one.
Nuprin’s disappearance was a business decision, not a regulatory action. The FDA did not order it removed, and Bristol-Myers Squibb issued no safety-related withdrawal. It was simply a brand that lost its competitive footing in a crowded market where the product itself was identical across every label.
Who Owns the Nuprin Name Now
The Nuprin trademark is still alive. It’s currently registered to Strides Global Consumer Healthcare Limited, a company based in Hertfordshire, England. Strides filed for the trademark in January 2019 and received registration in February 2020, covering pharmaceutical preparations including analgesic and ibuprofen products for oral use.
As of now, no widely available Nuprin-branded product has returned to U.S. store shelves. Owning a trademark doesn’t necessarily mean a company plans to launch a product immediately. It may be held for a future relaunch, licensing, or use in other markets. But the registration means the name hasn’t been abandoned entirely, and it’s possible Nuprin could reappear at some point under new ownership.